213 related articles for article (PubMed ID: 9174873)
21. Credentialing cosmeceuticals.
Draelos ZD
J Cosmet Dermatol; 2008 Dec; 7(4):245. PubMed ID: 19146598
[No Abstract] [Full Text] [Related]
22. Drugs to save your skin.
Sohn E
US News World Rep; 2004 Jan; 136(1):48-9. PubMed ID: 16116716
[No Abstract] [Full Text] [Related]
23. Cosmeceuticals: myths and misconceptions.
Newburger AE
Clin Dermatol; 2009; 27(5):446-52. PubMed ID: 19695475
[TBL] [Abstract][Full Text] [Related]
24. Update on drugs.
Skin Therapy Lett; 2000; 6(3):6. PubMed ID: 11252244
[No Abstract] [Full Text] [Related]
25. Long-term efficacy of biologics in the treatment of psoriasis: what do we really know?
Alwawi EA; Krulig E; Gordon KB
Dermatol Ther; 2009; 22(5):431-40. PubMed ID: 19845720
[TBL] [Abstract][Full Text] [Related]
26. Unapproved dermatologic indications for H2 receptor antagonists, cromolyn sodium, and ketotifen.
Paquette D; Rothe MJ
Clin Dermatol; 2000; 18(1):103-11. PubMed ID: 10701091
[No Abstract] [Full Text] [Related]
27. PICATO (ingenol mebutate 0.015% and 0.05% gels): a novel treatment for actinic keratosis.
Abramovits W; Oquendo M; Vincent KD; Gupta AK
Skinmed; 2013; 11(2):111-5. PubMed ID: 23745230
[No Abstract] [Full Text] [Related]
28. Vitamins A, B, C, D, E, F, trace elements and heavy metals: unapproved uses or indications.
Nicolaidou E; Katsambas AD
Clin Dermatol; 2000; 18(1):87-94. PubMed ID: 10701089
[No Abstract] [Full Text] [Related]
29. Statistical considerations in the design of clinical trials.
Clark C
Acta Derm Venereol Suppl (Stockh); 1971 May; 52(67):45-8. PubMed ID: 4947903
[No Abstract] [Full Text] [Related]
30. Drug treatments for skin disease introduced in 2003.
Skin Therapy Lett; 2004 Apr; 9(4):3-4. PubMed ID: 15146263
[No Abstract] [Full Text] [Related]
31. Arachidonate transforming and immunomodulating agents: unapproved uses or indications.
Lotti TM; Menchini G; Spallanzani A; Moretti S; Ghersetich I; Bianchi B
Clin Dermatol; 2000; 18(1):119-23. PubMed ID: 10701093
[No Abstract] [Full Text] [Related]
32. Lack of a US Food and Drug Administration indication should not limit access to appropriate treatment.
Albrecht J; Adamson AS; Barbieri JS; Bennett DD; Kiracofe EA; Kourosh AS; Leslie KS; Merola JF; Nguyen J; Siegfried E; Strickland N; Olbricht S; Asgari MM;
J Am Acad Dermatol; 2019 Feb; 80(2):577-578. PubMed ID: 30244066
[No Abstract] [Full Text] [Related]
33. Drug treatments for skin disease introduced in 2000.
Skin Therapy Lett; 2001 Feb; 6(5):4-6. PubMed ID: 11242138
[No Abstract] [Full Text] [Related]
34. [Principles of clinical testing of new dermatological preparations].
Sheklakov ND; Shakhtmeĭster IIa; Pokryshkin VI
Vestn Dermatol Venerol; 1984 Oct; (10):30-2. PubMed ID: 6516570
[No Abstract] [Full Text] [Related]
35. Hormones: androgens, antiandrogens, anabolic steroids, estrogens--unapproved uses or indications.
Güneş AT; Fetil E
Clin Dermatol; 2000; 18(1):55-61. PubMed ID: 10701086
[No Abstract] [Full Text] [Related]
36. U.S. Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis.
Meyerhoff A
Clin Infect Dis; 1999 Jan; 28(1):42-8; discussion 49-51. PubMed ID: 10028069
[TBL] [Abstract][Full Text] [Related]
37. Rising drug costs: the impact on dermatology.
Rico MJ
Skin Therapy Lett; 2000; 5(4):1-2,5. PubMed ID: 10785406
[TBL] [Abstract][Full Text] [Related]
38. Miscellaneous treatments: thalidomide, potassium iodide, levamisole, clofazimine, colchicine, and D-penicillamine.
Sanchez MR
Clin Dermatol; 2000; 18(1):131-45. PubMed ID: 10701095
[No Abstract] [Full Text] [Related]
39. Pediatric psoriasis: updates in biologic therapies.
Sukhatme SV; Gottlieb AB
Dermatol Ther; 2009; 22(1):34-9. PubMed ID: 19222515
[TBL] [Abstract][Full Text] [Related]
40. [Urea in dermatology II].
Müller KH; Pflugshaupt C
Hautarzt; 1989; 40 Suppl 9():13-9. PubMed ID: 2681073
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
